Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion ...
In today's ACT Brief, we examine regulatory uncertainty and 2026 breakthroughs shaping clinical research, reimagining CRO ...
Massachusetts-based CRO Veristat continued to expand its bench strength with the acquisition of biometrics trial specialist Instat Clinical Research. (NuProbe) Massachusetts-based CRO Veristat picked ...
In this free webinar, oncology experts will discuss what ASCO 2026 data could mean for cancer clinical trials and patient ...
SYDNEY--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development ...
Beyond Revenue Recognition: Rethinking CRO Contracting Through the CURED Shared Performance Contract
This article argues that improving financial outcomes—including more reliable revenue recognition—requires revisiting the ...
DUBLIN--(BUSINESS WIRE)--The "Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of ...
Atlanta-based Divergent CRO has launched and is offering services to biotech and medical device clients. (elenabs/GettyImages) Atlanta-based Divergent CRO has officially launched and is offering ...
For cosmetics brands and consumer research, SkinSecure™ adds an objective, physics-based biological measurement layer to efficacy panels that have traditionally relied on subjective grading or surface ...
A new 456-page report projects the global women's clinical trials and CRO market will grow from $9.9 billion in 2026 to $22.3 billion by 2036, as biomarker-driven research and decentralized trial ...
WEP Clinical (WEP), a full-service clinical research organization (CRO), today announced its sponsorship of National Patch ...
The biotech stocks get a lot of attention, from both stock analysts and investors, but the companies don’t exist in a vacuum. We are all familiar with their famously high overhead, but we might be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results